MedTrace Logo

A Study of BN102 in Patients With Previously Treated CLL/SLL and B-cell NHL

NCT05365100 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2023-03-24

No results posted yet for this study

Summary

This is a Multicenter Phase 1/2 Clinical Study to Evaluate the Safety and Efficacy of BN102 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and B-cell Non-Hodgkin's Lymphoma (NHL)

Conditions

  • CLL/SLL
  • NHL

Interventions

DRUG

BN102

oral tablets: BN102, BID

Sponsors & Collaborators

  • BioNova Pharmaceuticals (Shanghai) LTD.

    lead INDUSTRY

Principal Investigators

  • Weili Zhao, Prof. · Shanghai Jiaotong University school of Medicine, Ruijin Hospital

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-31
Primary Completion
2024-07-30
Completion
2024-07-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05365100 on ClinicalTrials.gov